MLXIPL and hepatocellular carcinoma: To further test the potential interest of inhibiting ChREBP activity using SBI-993 to improve sorafenib efficiency, we xenografted parental and SR-resistant SNU449, SNU475, Huh7 and SK-Hep1 HCC cells in nude mice and subsequently subjected them to sorafenib and/or SBI-993 treatment.